Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
It is a clinical decision, not a checkbox
A significant number of patients with multiple myeloma continue to relapse and become refractory to currently available therapies, representing one of the largest and most challenging unmet needs in the disease, Ester in t Groen, EMEA Therapeutic Area head, Haematology, at Johnson & Johnson, stated in a news release.1 Making teclistamab monotherapy available to patients as early as second line, where it has the potential to meaningfully improve long-term outcomes and change the course of the disease, could bring new hope to patients and their families. To view or add a comment, sign in 7,151 followers
Why Quality Standards Matter When choosing any supplement, you are essentially trusting that brand with your biology
She's getting impatient
You need to understand how each medication works at the receptor level, what the clinical trials actually show (not what marketing claims suggest), how side effect profiles compare, and which options are available right now versus still in development
US$ 27.46
US$ 23.49
US$ 21.10
US$ 21.91
US$ 27.32
